



IQWiG Reports – Commission No. H22-02

**Endoscopic ultrasound-guided
implantation via injection of
 ^{32}P -labeled microparticles for
unresectable, locally advanced
pancreatic cancer
Addendum to Commission H21-13¹**

Extract

¹ Translation of the executive summary of the addendum H22-02 *Endoskopische Injektions-Implantation von ^{32}P markierten Mikropartikeln bei irresektablen, lokal fortgeschrittenen Pankreastumoren – Addendum zum Auftrag H21-13* (Version 1.0; Status: 17 May 2022). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding.

Publishing details

Publisher

Institute for Quality and Efficiency in Health Care

Topic

Endoscopic ultrasound-guided implantation via injection of ³²P-labeled microparticles for unresectable, locally advanced pancreatic cancer – Addendum to Commission H21-13

Commissioning agency

Federal Joint Committee

Commission awarded on

23 March 2022

Internal Commission No.

H22-02

Address of publisher

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Im Mediapark 8
50670 Köln
Germany

Phone: +49 221 35685-0

Fax: +49 221 35685-1

E-mail: berichte@iqwig.de

Internet: www.iqwig.de

IQWiG employees involved in the addendum

- Anna Margraf
- Ulrike Lampert
- Gunnar Plinke
- Sibylle Sturtz
- Vera Weingärtner

Keywords: Brachytherapy, Pancreatic Neoplasms, Device Approval, Risk Assessment, Benefit Assessment

Executive summary

In a letter dated 24 March 2022, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG), as an addendum to commission H21-13, to examine the conclusions of the assessment according to §137h Social Code Book (SGB) V on the benefit, harmfulness and ineffectiveness of the method “endoscopic ultrasound-guided implantation via injection of ³²P-labeled microparticles for unresectable, locally advanced pancreatic cancer”.

Research question

The aim of the present investigation was to determine whether further relevant studies on the method “endoscopic ultrasound-guided implantation via injection of ³²P-labeled microparticles for unresectable, locally advanced pancreatic cancer” exist besides the documents already used in the §137h assessment H21-13. If this was the case, it was to be examined whether, taking these into account, still neither a benefit, harmfulness nor ineffectiveness could be identified for the examination or treatment method in question. Furthermore, it was to be examined whether, besides the studies already used in the §137h assessment, ongoing studies exist that are in principle suitable to provide relevant findings on the benefit, harmfulness or ineffectiveness of the method in the near future.

Methods

Randomized controlled trials (RCTs) were included that investigated the above method with regard to patient-relevant outcomes and that had not already been used in the assessment according to §137h.

A systematic literature search for studies was conducted in MEDLINE and the Cochrane Central Register of Controlled Trials. In parallel, a search for relevant systematic reviews was conducted in MEDLINE, the Cochrane Database of Systematic Reviews, the HTA Database as well as on the websites of the National Institute for Health and Care Excellence (NICE) and the Agency for Healthcare Research and Quality (AHRQ). The last search was conducted on 30 March 2022. In addition, the following information sources and search techniques were considered: study registries and screening of reference lists. The selection of relevant studies was performed by 2 reviewers independently of one another.

Information assessment and information synthesis and analysis were guided by the principles described in the Institute's General Methods.

Results

No additional relevant completed or ongoing studies were identified during information retrieval. There is no new information on the planned RCT OncoPac-2. We also refer to the §137h assessment H21-13.

One RCT with thematic proximity to the treatment method under assessment was identified. After closer examination, this RCT was excluded due to differences in the test intervention and other reasons, but is presented in the full report for information purposes.

Conclusion

After systematic examination, there is still no evidence of a benefit, ineffectiveness or harmfulness of the method “endoscopic ultrasound-guided implantation via injection of ³²P-labeled microparticles for unresectable, locally advanced pancreatic cancer”. Beyond the studies already considered in the §137h assessment, no additional completed or ongoing studies were found that would in principle be suitable to provide evidence of a benefit, ineffectiveness or harmfulness in the near future.

The full report (German version) is published under

<https://www.iqwig.de/projekte/h22-02.html>